FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptorpositive postmenopausal breast cancer - Bergh, J; Jönsson, P E; Lidbrink, E K (J Clin Oncol, 2012)
et al.